Arzneiwerk AG VIDA (XTER:TLIK) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Arzneiwerk AG VIDA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arzneiwerk AG VIDA's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Arzneiwerk AG VIDA ROCE % Historical Data

The historical data trend for Arzneiwerk AG VIDA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arzneiwerk AG VIDA ROCE % Chart

Arzneiwerk AG VIDA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

474.49

99.50

-16.92

-114.36

-211.33

Arzneiwerk AG VIDA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Arzneiwerk AG VIDA ROCE % Calculation

Arzneiwerk AG VIDA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.846	/	( ( (1.861 - 0.874)	+	(3.304 - 2.544) )	/ 2 )
	=	-1.846	/	( (0.987	+	0.76)	/ 2 )
	=	-1.846	/	0.8735
	=	-211.33 %

Arzneiwerk AG VIDA's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-0.284	/	( ( (12.459 - 15.649)	+	(12.148 - 14.58) )	/ 2 )
	=	-0.284	/	( ( -3.19	+	-2.432 )	/ 2 )
	=	-0.284	/	-2.811
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Arzneiwerk AG VIDA (XTER:TLIK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arzneiwerk AG VIDA ROCE % Related Terms

Thank you for viewing the detailed overview of Arzneiwerk AG VIDA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arzneiwerk AG VIDA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Arzneiwerk AG VIDA (XTER:TLIK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0NKY:UK TLIK:Germany

Address

Ordensmeisterstrasse 15-16, Berlin, DEU, 12099

Website

https://www.arzneiwerk.ag

Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe which usually includes high-priced drugs for chronic, complex, or rare diseases such as oncology, neurology, autoimmune diseases, ophthalmology, hemophilia, and infectious diseases.

Arzneiwerk AG VIDA Headlines

No Headlines